Immunotherapy Takes Hold in Frontline Advanced Nonsquamous NSCLC

Frontline immunotherapy has shown tremendous benefit in patients with advanced nonsquamous non–small cell lung cancer (NSCLC), but it should only be given in the absence of a driver mutation, according to Jyoti D. Patel, MD, FASCO.
... to read the full story